Fierce Healthcare reports that Aetion, which offers real-world evidence and analytics to drug companies, payers, life sciences companies, and regulatory agencies, scored $110 million in a series C funding round led by Warburg Pincus, a leading global growth equity firm, with additional investments from B Capital and Foresite Capital. Aetion’s existing backers New Enterprise Associates (NEA) and Flare Capital Partners also joined the round.
Read More
Read More